Stéphane Bancel, Moderna CEO (Nancy Lane/The Boston Herald via AP Images, Pool)
September 15, 2021 04:00 PM EDT
Coronavirus

At­tempt­ing to ride boost­er ad­comm coat­tails, Mod­er­na says its Covid-19 shot is bet­ter than Pfiz­er/BioN­Tech

Max Gelman

Senior Editor

As the FDA pre­pares to con­vene an ad­comm to dis­cuss Pfiz­er/BioN­Tech’s Covid-19 vac­cine boost­ers lat­er this week, the oth­er ma­jor mR­NA play­er is stick­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

A service from the Financial Times